ArticleHeliyon2023
Development of a maturity model for additive manufacturing: A conceptual model proposal.
Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Additive manufacturing (AM) is an emerging area with the potential to modify present business models in the near future. In contrast with conventional manufacturing (CM), AM allows the development of a product from a smaller amount of raw material, while allowing an improvement in properties in terms of weight and functionality. Its production flexibility and creativity in terms of materials have enabled not only the industry to use this technology, but also has been used in healthcare (e.g., in the production of human tissue) and by the final consumer. Despite the invaluable opportunities that this technology could provide, the uncertainties concerning its future developments and impacts on business models remain. New business models in AM will convey the need to: specialize the workforce in the design of new parts produced locally or remotely; regulation in the use and sharing of intellectual property rights by partner companies or between users; regulate the possibility of reverse engineering of highly customized products; etc. The present research proposes a conceptual maturity model to support the phases of evolution of AM in the industry, in supply chains, and in terms of open business models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.